QV Bioelectronics LTD.

QV Bioelectronics, a company in Manchester, is making a new medical device to treat brain cancer. The first type of brain cancer it will treat is glioblastoma. This is the most common brain cancer in adults. Very few people diagnosed with glioblastoma live for more than a year. The standard treatment for glioblastoma has been the same for 30 years. It inc...

Diffuse midline gliomas (DMG) are an extremely aggressive childhood brain cancer with a global incidence of 0.8/100,000, with around 30 UK diagnoses yearly. There is no cure, and the median age of diagnosis is 7 years old, with a median survival of just 6 months, increased to 9 months with radiation therapy. There is a dire lack of treatment options. Due ...

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and the 5-year survival rate is ~3.4%. Electric Field therapy (EFT) is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slow...

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and the 5-year survival rate is ~3.4%. Electrotherapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour rec...

I am the Principal Biomaterials scientist at QV Bioelectronics, and I am responsible for leading the development of the core technology. Following my undergraduate degree in Applied Pharmacology, I completed my PhD in bioengineering which focused on biomaterial fabrication and characterisation for osteoarthritis. Utilising my previous expertise, in my rol...

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average. Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interfe...

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. Even with the best available treatment, patients are only expected to live 14 months post-diagnosis. GBM is very difficult to treat, with the 5-year survival rate at 5%; by comparison, this figure is 89% for breast cancer. GBM patients are in desperate need for more effective treat...